

1 AN ACT concerning criminal law.

2 **Be it enacted by the People of the State of Illinois,**
3 **represented in the General Assembly:**

4 Section 5. The Illinois Controlled Substances Act is
5 amended by changing Section 204 as follows:

6 (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204)

7 Sec. 204. (a) The controlled substances listed in this
8 Section are included in Schedule I.

9 (b) Unless specifically excepted or unless listed in
10 another schedule, any of the following opiates, including
11 their isomers, esters, ethers, salts, and salts of isomers,
12 esters, and ethers, whenever the existence of such isomers,
13 esters, ethers and salts is possible within the specific
14 chemical designation:

15 (1) Acetylmethadol;

16 (1.1) Acetyl-alpha-methylfentanyl

17 (N-[1-(1-methyl-2-phenethyl)-

18 4-piperidinyl]-N-phenylacetamide);

19 (2) Allylprodine;

20 (3) Alphacetylmethadol, except

21 levo-alphacetylmethadol (also known as levo-alpha-

22 acetylmethadol, levomethadyl acetate, or LAAM);

23 (4) Alphameprodine;

- 1 (5) Alphamethadol;
- 2 (6) Alpha-methylfentanyl
- 3 (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
- 4 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
- 5 propanilido) piperidine;
- 6 (6.1) Alpha-methylthiofentanyl
- 7 (N-[1-methyl-2-(2-thienyl)ethyl-
- 8 4-piperidinyl]-N-phenylpropanamide);
- 9 (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
- 10 (7.1) PEPAP
- 11 (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
- 12 (8) Benzethidine;
- 13 (9) Betacetylmethadol;
- 14 (9.1) Beta-hydroxyfentanyl
- 15 (N-[1-(2-hydroxy-2-phenethyl)-
- 16 4-piperidinyl]-N-phenylpropanamide);
- 17 (10) Betameprodine;
- 18 (11) Betamethadol;
- 19 (12) Betaprodine;
- 20 (13) Clonitazene;
- 21 (14) Dextromoramide;
- 22 (15) Diampromide;
- 23 (16) Diethylthiambutene;
- 24 (17) Difenoazin;
- 25 (18) Dimenoxadol;
- 26 (19) Dimepheptanol;

- 1 (20) Dimethylthiambutene;
- 2 (21) Dioxaphetylbutyrate;
- 3 (22) Dipipanone;
- 4 (23) Ethylmethylthiambutene;
- 5 (24) Etonitazene;
- 6 (25) Etoxeridine;
- 7 (26) Furethidine;
- 8 (27) Hydroxypethidine;
- 9 (28) Ketobemidone;
- 10 (29) Levomoramide;
- 11 (30) Levophenacymorphan;
- 12 (31) 3-Methylfentanyl
- 13 (N-[3-methyl-1-(2-phenylethyl)-
- 14 4-piperidyl]-N-phenylpropanamide);
- 15 (31.1) 3-Methylthiofentanyl
- 16 (N-[(3-methyl-1-(2-thienyl)ethyl-
- 17 4-piperidinyl]-N-phenylpropanamide);
- 18 (32) Morpheridine;
- 19 (33) Noracymethadol;
- 20 (34) Norlevorphanol;
- 21 (35) Normethadone;
- 22 (36) Norpipanone;
- 23 (36.1) Para-fluorofentanyl
- 24 (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
- 25 4-piperidinyl]propanamide);
- 26 (37) Phenadoxone;

- 1 (38) Phenampromide;
- 2 (39) Phenomorphan;
- 3 (40) Phenoperidine;
- 4 (41) Piritramide;
- 5 (42) Proheptazine;
- 6 (43) Properidine;
- 7 (44) Propiram;
- 8 (45) Racemoramide;
- 9 (45.1) Thiofentanyl
- 10 (N-phenyl-N-[1-(2-thienyl)ethyl-
- 11 4-piperidinyl]-propanamide);
- 12 (46) Tilidine;
- 13 (47) Trimeperidine;
- 14 (48) Beta-hydroxy-3-methylfentanyl (other name:
- 15 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
- 16 N-phenylpropanamide);
- 17 (49) Furanyl fentanyl (FU-F);
- 18 (50) Butyryl fentanyl;
- 19 (51) Valeryl fentanyl;
- 20 (52) Acetyl fentanyl;
- 21 (53) Beta-hydroxy-thiofentanyl;
- 22 (54) 3,4-dichloro-N-[2-
- 23 (dimethylamino)cyclohexyl]-N-
- 24 methylbenzamide (U-47700);
- 25 (55) 4-chloro-N-[1-[2-
- 26 (4-nitrophenyl)ethyl]-2-piperidinylidene]-

1 benzenesulfonamide (W-18);
2 (56) 4-chloro-N-[1-(2-phenylethyl)
3 -2-piperidinylidene]-benzenesulfonamide (W-15);
4 (57) acrylfentanyl (acryloylfentanyl).

5 (c) Unless specifically excepted or unless listed in
6 another schedule, any of the following opium derivatives, its
7 salts, isomers and salts of isomers, whenever the existence of
8 such salts, isomers and salts of isomers is possible within
9 the specific chemical designation:

- 10 (1) Acetorphine;
- 11 (2) Acetyldihydrocodeine;
- 12 (3) Benzylmorphine;
- 13 (4) Codeine methylbromide;
- 14 (5) Codeine-N-Oxide;
- 15 (6) Cyprenorphine;
- 16 (7) Desomorphine;
- 17 (8) Diacetyldihydromorphine (Dihydroheroin);
- 18 (9) Dihydromorphine;
- 19 (10) Drotebanol;
- 20 (11) Etorphine (except hydrochloride salt);
- 21 (12) Heroin;
- 22 (13) Hydromorphenol;
- 23 (14) Methyldesorphine;
- 24 (15) Methyldihydromorphine;
- 25 (16) Morphine methylbromide;
- 26 (17) Morphine methylsulfonate;

1 (18) Morphine-N-Oxide;

2 (19) Myrophine;

3 (20) Nicocodeine;

4 (21) Nicomorphine;

5 (22) Normorphine;

6 (23) Pholcodine;

7 (24) Thebacon.

8 (d) Unless specifically excepted or unless listed in
9 another schedule, any material, compound, mixture, or
10 preparation which contains any quantity of the following
11 hallucinogenic substances, or which contains any of its salts,
12 isomers and salts of isomers, whenever the existence of such
13 salts, isomers, and salts of isomers is possible within the
14 specific chemical designation (for the purposes of this
15 paragraph only, the term "isomer" includes the optical,
16 position and geometric isomers):

17 (1) 3,4-methylenedioxyamphetamine

18 (alpha-methyl,3,4-methylenedioxyphenethylamine,
19 methylenedioxyamphetamine, MDA);

20 (1.1) Alpha-ethyltryptamine

21 (some trade or other names: etryptamine;

22 MONASE; alpha-ethyl-1H-indole-3-ethanamine;

23 3-(2-aminobutyl)indole; a-ET; and AET);

24 (2) 3,4-methylenedioxymethamphetamine (MDMA);

25 (2.1) 3,4-methylenedioxy-N-ethylamphetamine

26 (also known as: N-ethyl-alpha-methyl-

1 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
2 and MDEA);

3 (2.2) N-Benzylpiperazine (BZP);

4 (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);

5 (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);

6 (4) 3,4,5-trimethoxyamphetamine (TMA);

7 (5) (Blank);

8 (6) Diethyltryptamine (DET);

9 (7) Dimethyltryptamine (DMT);

10 (7.1) 5-Methoxy-diallyltryptamine;

11 (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);

12 (9) Ibogaine (some trade and other names:
13 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
14 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
15 indole; Tabernanthe iboga);

16 (10) Lysergic acid diethylamide;

17 (10.1) Salvinorin A;

18 (10.5) Salvia divinorum (meaning all parts of the
19 plant presently classified botanically as Salvia
20 divinorum, whether growing or not, the seeds thereof, any
21 extract from any part of that plant, and every compound,
22 manufacture, salts, isomers, and salts of isomers whenever
23 the existence of such salts, isomers, and salts of isomers
24 is possible within the specific chemical designation,
25 derivative, mixture, or preparation of that plant, its
26 seeds or extracts);

- 1 (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
- 2 (12) Peyote (meaning all parts of the plant presently
3 classified botanically as *Lophophora williamsii* Lemaire,
4 whether growing or not, the seeds thereof, any extract
5 from any part of that plant, and every compound,
6 manufacture, salts, derivative, mixture, or preparation of
7 that plant, its seeds or extracts);
- 8 (13) N-ethyl-3-piperidyl benzilate (JB 318);
- 9 (14) N-methyl-3-piperidyl benzilate;
- 10 (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
11 (also known as N-hydroxy-alpha-methyl-
12 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
- 13 (15) Parahexyl; some trade or other names:
14 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
15 dibenzo (b,d) pyran; Synhexyl;
- 16 (16) Psilocybin;
- 17 (17) Psilocyn;
- 18 (18) Alpha-methyltryptamine (AMT);
- 19 (19) 2,5-dimethoxyamphetamine
20 (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
- 21 (20) 4-bromo-2,5-dimethoxyamphetamine
22 (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
23 4-bromo-2,5-DMA);
- 24 (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
25 Some trade or other names: 2-(4-bromo-
26 2,5-dimethoxyphenyl)-1-aminoethane;

1 alpha-desmethyl DOB, 2CB, Nexus;

2 (21) 4-methoxyamphetamine

3 (4-methoxy-alpha-methylphenethylamine;

4 paramethoxyamphetamine; PMA);

5 (22) (Blank);

6 (23) Ethylamine analog of phencyclidine.

7 Some trade or other names:

8 N-ethyl-1-phenylcyclohexylamine,

9 (1-phenylcyclohexyl) ethylamine,

10 N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;

11 (24) Pyrrolidine analog of phencyclidine. Some trade

12 or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,

13 PHP;

14 (25) 5-methoxy-3,4-methylenedioxy-amphetamine;

15 (26) 2,5-dimethoxy-4-ethylamphetamine

16 (another name: DOET);

17 (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine

18 (another name: TCPy);

19 (28) (Blank);

20 (29) Thiophene analog of phencyclidine (some trade

21 or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;

22 2-thienyl analog of phencyclidine; TPCP; TCP);

23 (29.1) Benzothiophene analog of phencyclidine. Some

24 trade or other names: BTCP or benocyclidine;

25 (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);

26 (30) Bufotenine (some trade or other names:

1 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;

2 3-(2-dimethylaminoethyl)-5-indolol;

3 5-hydroxy-N,N-dimethyltryptamine;

4 N,N-dimethylserotonin; mappine);

5 (31) (Blank);

6 (32) (Blank);

7 (33) (Blank);

8 (34) (Blank);

9 (34.5) (Blank);

10 (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-

11 (2-methyloctan-2-yl)-6a,7,

12 10,10a-tetrahydrobenzo[c]chromen-1-ol

13 Some trade or other names: HU-210;

14 (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6-

15 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-

16 tetrahydrobenzo[c]chromen-1-ol, its isomers,

17 salts, and salts of isomers; Some trade or other

18 names: HU-210, Dexanabinol;

19 (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-

20 6,6-dimethyl-3-(2-methyloctan-2-yl)-

21 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol

22 Some trade or other names: HU-211;

23 (37) (Blank);

24 (38) (Blank);

25 (39) (Blank);

26 (40) (Blank);

1 (41) (Blank);

2 (42) Any compound structurally derived from
3 3-(1-naphthoyl)indole or
4 1H-indol-3-yl-(1-naphthyl)methane by substitution at the
5 nitrogen atom of the indole ring by alkyl, haloalkyl,
6 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
7 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
8 2-(4-morpholinyl)ethyl whether or not further substituted
9 in the indole ring to any extent, whether or not
10 substituted in the naphthyl ring to any extent. Examples
11 of this structural class include, but are not limited to,
12 JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;

13 (43) Any compound structurally derived from
14 3-(1-naphthoyl)pyrrole by substitution at the nitrogen
15 atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
16 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
17 halide, 1-(N-methyl-2-piperidinyl)methyl, or
18 2-(4-morpholinyl)ethyl, whether or not further substituted
19 in the pyrrole ring to any extent, whether or not
20 substituted in the naphthyl ring to any extent. Examples
21 of this structural class include, but are not limited to,
22 JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;

23 (44) Any compound structurally derived from
24 1-(1-naphthylmethyl)indene by substitution at the
25 3-position of the indene ring by alkyl, haloalkyl,
26 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,

1 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
2 2-(4-morpholinyl)ethyl whether or not further substituted
3 in the indene ring to any extent, whether or not
4 substituted in the naphthyl ring to any extent. Examples
5 of this structural class include, but are not limited to,
6 JWH-176;

7 (45) Any compound structurally derived from
8 3-phenylacetylindole by substitution at the nitrogen atom
9 of the indole ring with alkyl, haloalkyl, alkenyl,
10 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
11 halide, 1-(N-methyl-2-piperidinyl)methyl, or
12 2-(4-morpholinyl)ethyl, whether or not further substituted
13 in the indole ring to any extent, whether or not
14 substituted in the phenyl ring to any extent. Examples of
15 this structural class include, but are not limited to,
16 JWH-167, JWH-250, JWH-251, and RCS-8;

17 (46) Any compound structurally derived from
18 2-(3-hydroxycyclohexyl)phenol by substitution at the
19 5-position of the phenolic ring by alkyl, haloalkyl,
20 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
21 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
22 2-(4-morpholinyl)ethyl, whether or not substituted in the
23 cyclohexyl ring to any extent. Examples of this structural
24 class include, but are not limited to, CP 47, 497 and its
25 C8 homologue (cannabicyclohexanol);

26 (46.1) Any compound structurally derived from

1 3-(benzoyl) indole with substitution at the nitrogen atom
2 of the indole ring by an alkyl, haloalkyl, alkenyl,
3 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
4 halide, 1-(N-methyl-2-piperidinyl)methyl, or
5 2-(4-morpholinyl)ethyl group whether or not further
6 substituted in the indole ring to any extent and whether
7 or not substituted in the phenyl ring to any extent.
8 Examples of this structural class include, but are not
9 limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN
10 48,098), and RCS-4;

11 (47) (Blank);

12 (48) (Blank);

13 (49) (Blank);

14 (50) (Blank);

15 (51) (Blank);

16 (52) (Blank);

17 (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine.

18 Some trade or other names: 2C-T-7;

19 (53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some
20 trade or other names: 2C-E;

21 (53.2) 2,5-dimethoxy-4-methylphenethylamine. Some
22 trade or other names: 2C-D;

23 (53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some
24 trade or other names: 2C-C;

25 (53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade
26 or other names: 2C-I;

1 (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some
2 trade or other names: 2C-T-2;

3 (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine.
4 Some trade or other names: 2C-T-4;

5 (53.7) 2,5-dimethoxyphenethylamine. Some trade or
6 other names: 2C-H;

7 (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some
8 trade or other names: 2C-N;

9 (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some
10 trade or other names: 2C-P;

11 (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine.
12 Some trade or other names: 2C-G;

13 (53.11) The N-(2-methoxybenzyl) derivative of any 2C
14 phenethylamine referred to in subparagraphs (20.1), (53),
15 (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
16 (53.8), (53.9), and (53.10) including, but not limited to,
17 25I-NBOMe and 25C-NBOMe;

18 (54) 5-Methoxy-N,N-diisopropyltryptamine;

19 (55) (Blank);

20 (56) (Blank);

21 (57) (Blank);

22 (58) (Blank);

23 (59) 3-cyclopropoylindole with substitution at the
24 nitrogen atom of the indole ring by alkyl, haloalkyl,
25 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
26 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or

1 2-(4-morpholinyl)ethyl, whether or not further substituted
2 on the indole ring to any extent, whether or not
3 substituted on the cyclopropyl ring to any extent:
4 including, but not limited to, XLR11, UR144, FUB-144;

5 (60) 3-adamantoylindole with substitution at the
6 nitrogen atom of the indole ring by alkyl, haloalkyl,
7 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
8 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
9 2-(4-morpholinyl)ethyl, whether or not further substituted
10 on the indole ring to any extent, whether or not
11 substituted on the adamantyl ring to any extent:
12 including, but not limited to, AB-001;

13 (61) N-(adamantyl)-indole-3-carboxamide with
14 substitution at the nitrogen atom of the indole ring by
15 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
16 cycloalkylethyl, aryl halide, alkyl aryl halide,
17 1-(N-methyl-2-piperidinyl)methyl, or
18 2-(4-morpholinyl)ethyl, whether or not further substituted
19 on the indole ring to any extent, whether or not
20 substituted on the adamantyl ring to any extent:
21 including, but not limited to, APICA/2NE-1, STS-135;

22 (62) N-(adamantyl)-indazole-3-carboxamide with
23 substitution at a nitrogen atom of the indazole ring by
24 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
25 cycloalkylethyl, aryl halide, alkyl aryl halide,
26 1-(N-methyl-2-piperidinyl)methyl, or

1 2-(4-morpholinyl)ethyl, whether or not further substituted
2 on the indazole ring to any extent, whether or not
3 substituted on the adamantyl ring to any extent:
4 including, but not limited to, AKB48, 5F-AKB48;

5 (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester
6 with substitution at the nitrogen atom of the indole ring
7 by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
8 cycloalkylethyl, aryl halide, alkyl aryl halide,
9 1-(N-methyl-2-piperidinyl)methyl, or
10 2-(4-morpholinyl)ethyl, whether or not further substituted
11 on the indole ring to any extent, whether or not
12 substituted on the quinoline ring to any extent:
13 including, but not limited to, PB22, 5F-PB22, FUB-PB-22;

14 (64) 3-(1-naphthoyl)indazole with substitution at the
15 nitrogen atom of the indazole ring by alkyl, haloalkyl,
16 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
17 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
18 2-(4-morpholinyl)ethyl, whether or not further substituted
19 on the indazole ring to any extent, whether or not
20 substituted on the naphthyl ring to any extent: including,
21 but not limited to, THJ-018, THJ-2201;

22 (65) 2-(1-naphthoyl)benzimidazole with substitution
23 at the nitrogen atom of the benzimidazole ring by alkyl,
24 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
25 aryl halide, alkyl aryl halide,
26 1-(N-methyl-2-piperidinyl)methyl, or

1 2-(4-morpholinyl)ethyl, whether or not further substituted
2 on the benzimidazole ring to any extent, whether or not
3 substituted on the naphthyl ring to any extent: including,
4 but not limited to, FUBIMINA;

5 (66)

6 N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-
7 3-carboxamide with substitution on the nitrogen atom of
8 the indazole ring by alkyl, haloalkyl, alkenyl,
9 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
10 halide, 1-(N-methyl-2-piperidinyl)methyl, or
11 2-(4-morpholinyl)ethyl, whether or not further substituted
12 on the indazole ring to any extent: including, but not
13 limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;

14 (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-

15 indazole-3-carboxamide with substitution on the nitrogen
16 atom of the indazole ring by alkyl, haloalkyl, alkenyl,
17 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
18 halide, 1-(N-methyl-2-piperidinyl)methyl, or
19 2-(4-morpholinyl)ethyl, whether or not further substituted
20 on the indazole ring to any extent: including, but not
21 limited to, ADB-PINACA, ADB-FUBINACA;

22 (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-

23 indole-3-carboxamide with substitution on the nitrogen
24 atom of the indole ring by alkyl, haloalkyl, alkenyl,
25 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
26 halide, 1-(N-methyl-2-piperidinyl)methyl, or

1 2-(4-morpholinyl)ethyl, whether or not further substituted
2 on the indole ring to any extent: including, but not
3 limited to, ADBICA, 5F-ADBICA;

4 (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole-
5 3-carboxamide with substitution on the nitrogen atom of
6 the indole ring by alkyl, haloalkyl, alkenyl,
7 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
8 halide, 1-(N-methyl-2-piperidinyl)methyl, or
9 2-(4-morpholinyl)ethyl, whether or not further substituted
10 on the indole ring to any extent: including, but not
11 limited to, ABICA, 5F-ABICA;

12 (70) Methyl 2-(1H-indazole-3-carboxamido)-3-
13 methylbutanoate with substitution on the nitrogen atom of
14 the indazole ring by alkyl, haloalkyl, alkenyl,
15 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
16 halide, 1-(N-methyl-2-piperidinyl)methyl, or
17 2-(4-morpholinyl)ethyl, whether or not further substituted
18 on the indazole ring to any extent: including, but not
19 limited to, AMB, 5F-AMB;

20 (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3-
21 dimethylbutanoate with substitution on the nitrogen atom
22 of the indazole ring by alkyl, haloalkyl, alkenyl,
23 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
24 halide, 1-(N-methyl-2-piperidinyl)methyl, or
25 2-(4-morpholinyl)ethyl, whether or not further substituted
26 on the indazole ring to any extent: including, but not

1 limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;

2 (72) Methyl 2-(1H-indole-3-carboxamido)-3-
3 methylbutanoate with substitution on the nitrogen atom of
4 the indole ring by alkyl, haloalkyl, alkenyl,
5 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
6 halide, 1-(N-methyl-2-piperidinyl)methyl, or
7 2-(4-morpholinyl)ethyl, whether or not further substituted
8 on the indazole ring to any extent: including, but not
9 limited to, MMB018, MMB2201, and AMB-CHMICA;

10 (73) Methyl 2-(1H-indole-3-carboxamido)-3,3-
11 dimethylbutanoate with substitution on the nitrogen atom
12 of the indole ring by alkyl, haloalkyl, alkenyl,
13 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
14 halide, 1-(N-methyl-2-piperidinyl)methyl, or
15 2-(4-morpholinyl)ethyl, whether or not further substituted
16 on the indazole ring to any extent: including, but not
17 limited to, MDMB-CHMICA;

18 (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-
19 indazole-3-carboxamide with substitution on the nitrogen
20 atom of the indazole ring by alkyl, haloalkyl, alkenyl,
21 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
22 halide, 1-(N-methyl-2-piperidinyl)methyl, or
23 2-(4-morpholinyl)ethyl, whether or not further substituted
24 on the indazole ring to any extent: including, but not
25 limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;

26 (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole-

1 3-carboxamide with substitution on the nitrogen atom of
2 the indole ring by alkyl, haloalkyl, alkenyl,
3 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
4 halide, 1-(N-methyl-2-piperidinyl)methyl, or
5 2-(4-morpholinyl)ethyl, whether or not further substituted
6 on the indazole ring to any extent: including, but not
7 limited to, APP-PICA and 5-fluoro-APP-PICA;

8 (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
9 4-AcO-DMT;

10 (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade
11 name 5-MeO-MIPT;

12 (78) 4-hydroxy Diethyltryptamine (4-HO-DET);

13 (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);

14 (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);

15 (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
16 (4-HO-MiPT);

17 (82) Fluorophenylpiperazine;

18 (83) Methoxetamine;

19 (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso-
20 ethcathinone).

21 (e) Unless specifically excepted or unless listed in
22 another schedule, any material, compound, mixture, or
23 preparation which contains any quantity of the following
24 substances having a depressant effect on the central nervous
25 system, including its salts, isomers, and salts of isomers
26 whenever the existence of such salts, isomers, and salts of

1 isomers is possible within the specific chemical designation:

2 (1) mecloqualone;

3 (2) methaqualone; and

4 (3) gamma hydroxybutyric acid.

5 (f) Unless specifically excepted or unless listed in
6 another schedule, any material, compound, mixture, or
7 preparation which contains any quantity of the following
8 substances having a stimulant effect on the central nervous
9 system, including its salts, isomers, and salts of isomers:

10 (1) Fenethylamine;

11 (2) N-ethylamphetamine;

12 (3) Aminorex (some other names:

13 2-amino-5-phenyl-2-oxazoline; aminoxaphen;

14 4-5-dihydro-5-phenyl-2-oxazolamine) and its

15 salts, optical isomers, and salts of optical isomers;

16 (4) Methcathinone (some other names:

17 2-methylamino-1-phenylpropan-1-one;

18 Ephedrone; 2-(methylamino)-propionophenone;

19 alpha-(methylamino)propionophenone; N-methylcathinone;

20 methcathinone; Monomethylpropion; UR 1431) and its

21 salts, optical isomers, and salts of optical isomers;

22 (5) Cathinone (some trade or other names:

23 2-aminopropionophenone; alpha-aminopropionophenone;

24 2-amino-1-phenyl-propanone; norephedrone);

25 (6) N,N-dimethylamphetamine (also known as:

26 N,N-alpha-trimethyl-benzeneethanamine;

1 N,N-alpha-trimethylphenethylamine);

2 (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
3 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);

4 (8) 3,4-Methylenedioxypropylamphetamine (MDPV);

5 (9) Halogenated amphetamines and
6 methamphetamines - any compound derived from either
7 amphetamine or methamphetamine through the substitution
8 of a halogen on the phenyl ring, including, but not
9 limited to, 2-fluoroamphetamine, 3-
10 fluoroamphetamine and 4-fluoroamphetamine;

11 (10) Aminopropylbenzofuran (APB):
12 including 4-(2-Aminopropyl) benzofuran, 5-
13 (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
14 benzofuran, and 7-(2-Aminopropyl) benzofuran;

15 (11) Aminopropyl-dihydrobenzofuran (APDB):
16 including 4-(2-Aminopropyl)-2,3-dihydrobenzofuran,
17 5-(2-Aminopropyl)-2,3-dihydrobenzofuran,
18 6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
19 and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran;

20 (12) Methylaminopropylbenzofuran
21 (MAPB): including 4-(2-methylaminopropyl)
22 benzofuran, 5-(2-methylaminopropyl)benzofuran,
23 6-(2-methylaminopropyl)benzofuran
24 and 7-(2-methylaminopropyl)benzofuran.

25 (g) Temporary listing of substances subject to emergency
26 scheduling. Any material, compound, mixture, or preparation

1 that contains any quantity of the following substances:

2 (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
3 (benzylfentanyl), its optical isomers, isomers, salts, and
4 salts of isomers;

5 (2) N-[1(2-thienyl) methyl-4-piperidyl]-N-
6 phenylpropanamide (thenylfentanyl), its optical isomers,
7 salts, and salts of isomers.

8 (h) Synthetic cathinones. Unless specifically excepted,
9 any chemical compound which is not approved by the United
10 States Food and Drug Administration or, if approved, is not
11 dispensed or possessed in accordance with State or federal
12 law, not including bupropion, structurally derived from
13 2-aminopropan-1-one by substitution at the 1-position with
14 either phenyl, naphthyl, or thiophene ring systems, whether or
15 not the compound is further modified in one or more of the
16 following ways:

17 (1) by substitution in the ring system to any extent
18 with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or
19 halide substituents, whether or not further substituted in
20 the ring system by one or more other univalent
21 substituents. Examples of this class include, but are not
22 limited to, 3,4-Methylenedioxycathinone (bk-MDA);

23 (2) by substitution at the 3-position with an acyclic
24 alkyl substituent. Examples of this class include, but are
25 not limited to, 2-methylamino-1-phenylbutan-1-one
26 (buphedrone); or

1 (3) by substitution at the 2-amino nitrogen atom with
2 alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by
3 inclusion of the 2-amino nitrogen atom in a cyclic
4 structure. Examples of this class include, but are not
5 limited to, Dimethylcathinone, Ethcathinone, and
6 a-Pyrrolidinopropiophenone (a-PPP); or

7 Any other synthetic cathinone which is not approved by the
8 United States Food and Drug Administration or, if approved, is
9 not dispensed or possessed in accordance with State or federal
10 law.

11 (i) Synthetic cannabinoids or piperazines. Any synthetic
12 cannabinoid or piperazine which is not approved by the United
13 States Food and Drug Administration or, if approved, which is
14 not dispensed or possessed in accordance with State and
15 federal law.

16 (j) Unless specifically excepted or listed in another
17 schedule, any chemical compound which is not approved by the
18 United States Food and Drug Administration or, if approved, is
19 not dispensed or possessed in accordance with State or federal
20 law, and is derived from the following structural classes and
21 their salts:

22 (1) Benzodiazepine class: A fused 1,4-diazepine and
23 benzene ring structure with a phenyl connected to the
24 1,4-diazepine ring, with any substitution(s) or
25 replacement(s) on the 1,4-diazepine or benzene ring, any
26 substitution(s) on the phenyl ring, or any combination

1 thereof. Examples of this class include but are not
2 limited to: Clonazolam, Flualprazolam; or

3 (2) Thienodiazepine class: A fused 1,4-diazepine and
4 thiophene ring structure with a phenyl connected to the
5 1,4-diazepine ring, with any substitution(s) or
6 replacement(s) on the 1,4-diazepine or thiophene ring, any
7 substitution(s) on the phenyl ring, or any combination
8 thereof. Examples of this class include but are not
9 limited to: Etizolam.

10 (Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17;
11 100-368, eff. 1-1-18; 100-789, eff. 1-1-19; 100-863, eff.
12 8-14-18.)